210 related articles for article (PubMed ID: 25880284)
1. Discovery and anti-cancer evaluation of two novel non-ATP-competitive FGFR1 inhibitors in non-small-cell lung cancer.
Wu J; Wei T; Tang Q; Weng B; Li W; Jiang X; Ding T; Li X; Liang G; Cai Y; Ji J
BMC Cancer; 2015 Apr; 15():276. PubMed ID: 25880284
[TBL] [Abstract][Full Text] [Related]
2. The therapeutic potential of a novel non-ATP-competitive fibroblast growth factor receptor 1 inhibitor on gastric cancer.
Xu C; Li W; Qiu P; Xia Y; Du X; Wang F; Shen L; Chen Q; Zhao Y; Jin R; Wu J; Liang G; Li X
Anticancer Drugs; 2015 Apr; 26(4):379-87. PubMed ID: 25521558
[TBL] [Abstract][Full Text] [Related]
3. Discovery and identification of new non-ATP competitive FGFR1 inhibitors with therapeutic potential on non-small-cell lung cancer.
Wang Y; Cai Y; Ji J; Liu Z; Zhao C; Zhao Y; Wei T; Shen X; Zhang X; Li X; Liang G
Cancer Lett; 2014 Mar; 344(1):82-89. PubMed ID: 24513267
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of 4-bromo-N-(3,5-dimethoxyphenyl)benzamide derivatives as novel FGFR1 inhibitors for treatment of non-small cell lung cancer.
Xie Z; Cheng D; Luo L; Shen G; Pan S; Pan Y; Chen B; Wang X; Liu Z; Zhang Y; Ye F
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):905-919. PubMed ID: 29734851
[TBL] [Abstract][Full Text] [Related]
5. Discovery of 4,6-pyrimidinediamine derivatives as novel dual EGFR/FGFR inhibitors aimed EGFR/FGFR1-positive NSCLC.
Xie Z; Wu K; Wang Y; Pan Y; Chen B; Cheng D; Pan S; Guo T; Du X; Fang L; Wang X; Ye F
Eur J Med Chem; 2020 Feb; 187():111943. PubMed ID: 31846829
[TBL] [Abstract][Full Text] [Related]
6. Novel FGFR inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing FGFR1.
Ren M; Hong M; Liu G; Wang H; Patel V; Biddinger P; Silva J; Cowell J; Hao Z
Oncol Rep; 2013 Jun; 29(6):2181-90. PubMed ID: 23563700
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel non-ATP competitive FGFR1 inhibitors and evaluation of their anti-tumor activity in non-small cell lung cancer in vitro and in vivo.
Wu J; Ji J; Weng B; Qiu P; Kanchana K; Wei T; Wang Y; Cai Y; Li X; Liang G
Oncotarget; 2014 Jun; 5(12):4543-53. PubMed ID: 24980830
[TBL] [Abstract][Full Text] [Related]
8. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.
Zhang J; Zhang L; Su X; Li M; Xie L; Malchers F; Fan S; Yin X; Xu Y; Liu K; Dong Z; Zhu G; Qian Z; Tang L; Schöttle J; Zhan P; Ji Q; Kilgour E; Smith PD; Brooks AN; Thomas RK; Gavine PR
Clin Cancer Res; 2012 Dec; 18(24):6658-67. PubMed ID: 23082000
[TBL] [Abstract][Full Text] [Related]
9. A novel non-ATP competitive FGFR1 inhibitor with therapeutic potential on gastric cancer through inhibition of cell proliferation, survival and migration.
Wu J; Du X; Li W; Zhou Y; Bai E; Kang Y; Chen Q; Fu W; Yun D; Xu Q; Qiu P; Jin R; Cai Y; Liang G
Apoptosis; 2017 Jun; 22(6):852-864. PubMed ID: 28315172
[TBL] [Abstract][Full Text] [Related]
10. Combination effects of arsenic trioxide and fibroblast growth factor receptor inhibitor in squamous cell lung carcinoma.
Lam SK; Leung LL; Li YY; Zheng CY; Ho JC
Lung Cancer; 2016 Nov; 101():111-119. PubMed ID: 27794399
[TBL] [Abstract][Full Text] [Related]
11. Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer.
Adachi Y; Watanabe K; Kita K; Kitai H; Kotani H; Sato Y; Inase N; Yano S; Ebi H
Carcinogenesis; 2017 Oct; 38(11):1063-1072. PubMed ID: 28968756
[TBL] [Abstract][Full Text] [Related]
12. Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC.
Singleton KR; Hinz TK; Kleczko EK; Marek LA; Kwak J; Harp T; Kim J; Tan AC; Heasley LE
Cancer Res; 2015 Oct; 75(20):4398-406. PubMed ID: 26359452
[TBL] [Abstract][Full Text] [Related]
13. A novel FGFR1-binding peptide exhibits anti-tumor effect on lung cancer by inhibiting proliferation and angiogenesis.
Tan Q; Wang Z; Wang Q; Wang Y; Huang Z; Su N; Jin M; Kuang L; Qi H; Ni Z; Li C; Zhu Y; Jiang W; Chen H; Deng C; Du X; Xie Y; Chen L
Int J Biol Sci; 2018; 14(10):1389-1398. PubMed ID: 30123084
[TBL] [Abstract][Full Text] [Related]
14. Potential Antitumor Activity of SIM-89 in Non-Small Cell Lung Cancer Cells.
Pei J; Chu T; Shao M; Teng J; Sha H; Gu A; Li R; Qian J; Mao W; Li Y; Han B
Yonsei Med J; 2017 May; 58(3):581-591. PubMed ID: 28332364
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, biological evaluation, QSAR and molecular dynamics simulation studies of potential fibroblast growth factor receptor 1 inhibitors for the treatment of gastric cancer.
Ying S; Du X; Fu W; Yun D; Chen L; Cai Y; Xu Q; Wu J; Li W; Liang G
Eur J Med Chem; 2017 Feb; 127():885-899. PubMed ID: 27829519
[TBL] [Abstract][Full Text] [Related]
16. Ferulic Acid Exerts Anti-Angiogenic and Anti-Tumor Activity by Targeting Fibroblast Growth Factor Receptor 1-Mediated Angiogenesis.
Yang GW; Jiang JS; Lu WQ
Int J Mol Sci; 2015 Oct; 16(10):24011-31. PubMed ID: 26473837
[TBL] [Abstract][Full Text] [Related]
17. Biological evaluation of 2-arylidene-4, 7-dimethyl indan-1-one (FXY-1): a novel Akt inhibitor with potent activity in lung cancer.
Rajagopalan P; Alahmari KA; Elbessoumy AA; Balasubramaniam M; Suresh R; Shariff ME; Chandramoorthy HC
Cancer Chemother Pharmacol; 2016 Feb; 77(2):393-404. PubMed ID: 26781309
[TBL] [Abstract][Full Text] [Related]
18. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
Shirsath N; Rathos M; Chaudhari U; Sivaramakrishnan H; Joshi K
Lung Cancer; 2013 Nov; 82(2):214-21. PubMed ID: 24051085
[TBL] [Abstract][Full Text] [Related]
19. Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines.
Morgillo F; Sasso FC; Della Corte CM; Vitagliano D; D'Aiuto E; Troiani T; Martinelli E; De Vita F; Orditura M; De Palma R; Ciardiello F
Clin Cancer Res; 2013 Jul; 19(13):3508-19. PubMed ID: 23695170
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of protein kinase C α/βII and activation of c-Jun NH2-terminal kinase mediate glycyrrhetinic acid induced apoptosis in non-small cell lung cancer NCI-H460 cells.
Song J; Ko HS; Sohn EJ; Kim B; Kim JH; Kim HJ; Kim C; Kim JE; Kim SH
Bioorg Med Chem Lett; 2014 Feb; 24(4):1188-91. PubMed ID: 24461294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]